<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04178577</url>
  </required_header>
  <id_info>
    <org_study_id>SPR994-102</org_study_id>
    <nct_id>NCT04178577</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Pharmacokinetics and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees of Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spero Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spero Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the pharmacokinetics (PK) of TBPM-PI-HBr in subjects with normal renal
      function, subjects with various degrees of renal insufficiency, and subjects with end-stage
      renal disease (ESRD) receiving hemodialysis (HD) therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apparent total body clearance (CL/F).</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve from time zero to the last quantifiable sample (AUC0-last).</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve extrapolated to infinity (AUC0-∞).</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent steadystate volume of distribution (Vss/F).</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax).</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the maximum plasma concentration (Tmax).</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination half-life (t1/2).</measure>
    <time_frame>72 hours post dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent AEs (including SAEs) categorized by severity and relationship to study drug.</measure>
    <time_frame>14 days post last dose</time_frame>
    <description>AEs will be categorized by system organ class (SOC) and AE preferred term (PT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant changes from baseline in clinical laboratory values.</measure>
    <time_frame>14 days post last dose</time_frame>
    <description>All laboratory data will be summarized by cohort, and at each scheduled time-point using descriptive statistics (n, mean, SD, median, minimum, and maximum).
E.g. of laboratory values: hematology, biochemistry, coagulation and urinalysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant changes from baseline in physical examination.</measure>
    <time_frame>14 days post last dose</time_frame>
    <description>Changes in baseline in physical examination findings (Normal, Abnormal NCS, Abnormal CS) will be summarized using counts and percentages by cohort, and will also be listed individually for each scheduled time-point.
Physical examination will include: HEENT; cardiovascular, respiratory, gastrointestinal, dermatological, musculoskeletal, nervous systems, lymph nodes and general appearance. Additional body systems may be evaluated at the Investigator's discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant changes from baseline in vitals signs.</measure>
    <time_frame>14 days post last dose</time_frame>
    <description>Vital sign values and changes from baseline at each scheduled time-point will be summarized by cohort for the Safety Analysis Population using descriptive statistics (n, mean, SD, median, minimum, and maximum).
Vitals signs will include: systolic and diastolic blood pressure, heart rate, respiratory rate, and temperature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant changes from baseline in ECG</measure>
    <time_frame>14 days post last dose</time_frame>
    <description>Overall evaluation of safety ECGs will be summarized by cohort, using frequency counts and percentage of subjects as normal or abnormal, and the relevance of the abnormality will be summarized by CS or NCS.
ECG parameters will include: heart rate, RR interval, PR interval, QRS, QT and QTcF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of drug excreted in the urine expressed as a percentage of the TBPM-PI-HBr dose administered (Ae%).</measure>
    <time_frame>72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of drug excreted in the urine through 24 hours (Ae0-24), through 48 hours (Ae0-48) and through 72 hours (Ae0-72) for Cohorts 1-4.</measure>
    <time_frame>72 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects on dialysis, estimated hemodialysis clearance (CLHD) will be assessed.</measure>
    <time_frame>Up to 1 day post dose - between start and end of hemodialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects on dialysis, the extraction ratio (ER) will be assessed.</measure>
    <time_frame>Up to 1 day post dose - between start and end of hemodialysis.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects on dialysis, the amount of the dose removed by hemodialysis (XHD) will be assessed.</measure>
    <time_frame>Up to 1 day post dose - between start and end of hemodialysis.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)</intervention_name>
    <description>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.</description>
    <arm_group_label>Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)</arm_group_label>
    <other_name>TBPM-PI-HBr</other_name>
    <other_name>SPR994</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Adult males or females, 18 years of age or older.

          -  BMI ≥ 18.5 and ≤ 39.9 (kg/m2) and weight between 50.0 and 130.0 kg

          -  Medically healthy without clinically significant abnormalities (Healthy Volunteers) or
             medically stable without clinically significant acute or chronic illness (Subjects
             with Renal Disease).

          -  Non-smoker for at least 1 month prior to screening for the study.

          -  Ability and willingness to abstain from alcohol, caffeine, xanthinecontaining
             beverages or food.

        Key Exclusion Criteria:

          -  Any clinically significant medical history or abnormal findings upon physical
             examination, or clinical laboratory tests, not specifically excluded in other criteria
             below that, in the opinion of the Investigator, might confound the results of the
             study or pose an additional risk in administering study drug to the subject.

          -  Electrocardiogram (ECG) with QTcF interval duration equal or greater than 500 msec

          -  Hemoglobin (HB), hematocrit (HCT), white blood cell count (WBC), or platelet count
             less than the lower limit of normal range of the reference laboratory (Cohort 1). HB &lt;
             8.5 gm/dL, WBC ≤ 3,000 cells/μL or platelet count ≤ 100,000 cells/μL (Cohorts 2-5).

          -  Results of biochemistry tests for alanine aminotransferase (ALT), aspartate
             aminotransferase (AST) and bilirubin greater than 1.5 X the upper limit of normal
             (ULN) for the reference laboratory.

          -  Recent history of known or suspected Clostridium difficile infection.

          -  History of known genetic metabolism anomaly associated with carnitine deficiency
             (e.g., carnitine transporter defect, methylmalonic aciduria, propionic academia).

          -  History of chronic liver disease, cirrhosis, or biliary disease.

          -  History of seizure disorder except childhood history of febrile seizures.

          -  Positive urine drug/alcohol testing.

          -  Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen
             (HBsAg) or hepatitis C (HCV) antibodies.

          -  History of substance abuse or alcohol abuse.

          -  Use of antacids within 24 hours prior to study drug administration.

          -  Known history of clinically significant hypersensitivity reaction or anaphylaxis to
             any medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Melnick, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Spero Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Floni Bajraktari</last_name>
    <phone>+1 (857) 242-1557</phone>
    <email>fbajraktari@sperotherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Facility</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2019</study_first_posted>
  <last_update_submitted>December 26, 2019</last_update_submitted>
  <last_update_submitted_qc>December 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End State Renal Disease (ESRD)</keyword>
  <keyword>Renal Insufficiency</keyword>
  <keyword>Renal Impairment</keyword>
  <keyword>Renal Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

